Dermata Income Tax Expense from 2010 to 2025

DRMAW Stock  USD 0.03  0.0001  0.33%   
Dermata Therapeutics Income Tax Expense yearly trend continues to be fairly stable with very little volatility. Income Tax Expense is likely to outpace its year average in 2025. During the period from 2010 to 2025, Dermata Therapeutics Income Tax Expense regression line of quarterly data had mean square error of 4.4 B and geometric mean of  93,520. View All Fundamentals
 
Income Tax Expense  
First Reported
2010-12-31
Previous Quarter
-7.2 K
Current Value
-6.9 K
Quarterly Volatility
117.8 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Dermata Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dermata Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 245.7 K, Depreciation And Amortization of 9.7 M or Interest Expense of 111.4 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.26. Dermata financial statements analysis is a perfect complement when working with Dermata Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Dermata Therapeutics Correlation against competitors.
For more information on how to buy Dermata Stock please use our How to Invest in Dermata Therapeutics guide.

Latest Dermata Therapeutics' Income Tax Expense Growth Pattern

Below is the plot of the Income Tax Expense of Dermata Therapeutics Warrant over the last few years. It is Dermata Therapeutics' Income Tax Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Dermata Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Income Tax Expense10 Years Trend
Slightly volatile
   Income Tax Expense   
197.3K45.6K-9.7K-8.0K-7.2K-6.9K100%
       Timeline  

Dermata Income Tax Expense Regression Statistics

Arithmetic Mean169,908
Geometric Mean93,520
Coefficient Of Variation69.32
Mean Deviation104,470
Median250,748
Standard Deviation117,785
Sample Variance13.9B
Range260.4K
R-Value(0.84)
Mean Square Error4.4B
R-Squared0.70
Significance0.000049
Slope(20,753)
Total Sum of Squares208.1B

Dermata Income Tax Expense History

2025 -6875.83
2024 -7237.72
2023 -8041.91
2022 -9674.49
202145.6 K
2020197.3 K

About Dermata Therapeutics Financial Statements

Dermata Therapeutics investors use historical fundamental indicators, such as Dermata Therapeutics' Income Tax Expense, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Dermata Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Income Tax Expense-7.2 K-6.9 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Dermata Stock Analysis

When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.